What question did this study set out to answer?

To assess long-term response rates, response duration, treatment failure, retreatment efficacy, second malignancies, and overall survival in patients with hairy cell leukemia treated with cladribine.

September 15, 1998Blood

Long-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment

View Full Paper

Ask AI

Bookmark

Authors

ASAlan SavenScripps Clinic CBCarol BurianScripps MD Anderson Cancer Center JKJames A. KoziolRoyal Children's Hospital

Discussion

Member takes

Implication

Clinical study demonstrates durable complete remissions and 96% four-year survival in hairy cell leukemia after cladribine, indicating high long-term therapeutic efficacy.

Key Points

To assess long-term response rates, response duration, treatment failure, retreatment efficacy, second malignancies, and overall survival in patients with hairy cell leukemia treated with cladribine.
Treated 358 patients with hairy cell leukemia with cladribine at 0.087 or 0.1 mg/kg/day via continuous intravenous infusion for 7 days at a single center.
Tracked treatment response, time-to-treatment failure, and retreatment outcomes across an overall median response follow-up of 52 months.
Compared observed incidence of second neoplasms against expected rates derived from National Cancer Institute SEER data.
Of 349 evaluable patients, 91% (n=319) achieved complete response and 7% (n=22) achieved partial response, with an overall 48-month survival rate of 96%.
Time-to-treatment failure at 48 months was 19% overall, measuring 16% in complete responders and 54% in partial responders; retreatment in 53 relapsed patients achieved a 62% complete response rate.
Second neoplasms occurred in 8% of patients (n=27) with an observed-to-expected ratio of 1.88 (95% CI, 1.24 to 2.74).

Cite This Study

Saven et al. (1998) studied this question.

synapsesocial.com/papers/6a71a053ac440176ef2a41b5 https://doi.org/10.1182/blood.v92.6.1918

View Full Paper

Ask AI

Bookmark

Implication

Clinical study demonstrates durable complete remissions and 96% four-year survival in hairy cell leukemia after cladribine, indicating high long-term therapeutic efficacy.

Long-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

Long-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider